GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Liver Transplantation/AASLD–AST Guideline on Adult Liver Transplant Candidate Evaluation

AASLD–AST Guideline on Adult Liver Transplant Candidate Evaluation

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated December 1, 2025

Quick Answer

The AASLD–AST Guideline on Adult Liver Transplant Candidate Evaluation provides a comprehensive, evidence-based framework for assessing patients who may benefit from liver transplantation. This updated guideline, developed by a multidisciplinary expert panel, reflects advancements in transplantation medicine, evolving patient populations, and ethical considerations since the previous 2005 guidance.


The AASLD–AST Guideline on Adult Liver Transplant Candidate Evaluation provides a comprehensive, evidence-based framework for assessing patients who may benefit from liver transplantation. This updated guideline, developed by a multidisciplinary expert panel, reflects advancements in transplantation medicine, evolving patient populations, and ethical considerations since the previous 2005 guidance. It emphasizes equity, utility, and improving patient outcomes while ensuring consistent and transparent practices across transplant centers.

### Key Highlights of the Guideline:

#### 1. **Indications for Referral to a Transplant Center**

  • **Decompensated Cirrhosis**: Patients with liver disease complications such as ascites, variceal bleeding, or hepatic encephalopathy should be referred.
  • **Acute-on-Chronic Liver Failure (ACLF)**: These patients should be considered for evaluation due to their high risk of mortality.
  • **Acute Liver Failure (ALF)**: This condition requires **urgent referral** to a transplant center due to its rapid progression and life-threatening nature.
  • **Hepatocellular Carcinoma (HCC)**: Patients with liver cancer, particularly those within transplant criteria (e.g., Milan criteria), are candidates for evaluation.
  • **Select Cholangiocarcinoma Cases**: Patients with early-stage cholangiocarcinoma may also be considered for transplantation.
  • **Portal Hypertensive Complications or Quality-of-Life Impairment**: Even in cases with low MELD (Model for End-Stage Liver Disease) scores, these factors should prompt consideration for referral.

#### 2. **Principles of Candidate Evaluation**

  • The evaluation process focuses on:
  • **Prognosis Without Transplantation**: Assessing the likelihood of survival without a transplant.
  • **Post-Transplant Benefit**: Determining the potential for improved survival and quality of life after transplantation.
  • **Patient Preferences**: Incorporating the patient’s values, preferences, and goals of care into the decision-making process.
  • A **comprehensive multidisciplinary approach** is strongly recommended for evaluating candidates.

#### 3. **Components of the Evaluation Process**

The guideline recommends a thorough, multidisciplinary assessment to optimize outcomes:

  • **Cardiopulmonary Assessment**: Evaluating cardiovascular and pulmonary health to ensure suitability for surgery and recovery.
  • **Infection Screening**: Identifying and managing potential infections that could complicate transplantation.
  • **Cancer Surveillance**: Screening for malignancies to ensure they are within transplantable criteria.
  • **Nutrition and Frailty Assessment**: Evaluating nutritional status and physical frailty, as these factors can influence transplant outcomes.
  • **Bone Health**: Assessing for osteoporosis or other bone conditions that may impact recovery.
  • **Dental Health**: Ensuring oral health to minimize the risk of post-transplant infections.
  • **Psychosocial Assessment**: Addressing mental health, substance use disorders, social support, and adherence potential.

#### 4. **Addressing Potential Contraindications**

  • The guideline emphasizes that certain conditions are **not absolute contraindications** to transplantation, provided the associated risks are managed effectively:
  • **Frailty**: While frailty is a risk factor, it is not an exclusion criterion if interventions can improve the patient’s condition.
  • **Mental Health Disorders**: These should be evaluated and treated but are not a reason to deny transplantation.
  • **Substance Use Disorders**: Patients with a history of substance use can be considered if they demonstrate sustained recovery and adherence potential.
  • **Extremes of BMI**: Obesity or underweight status should not automatically disqualify patients, though weight optimization may be necessary.

#### 5. **Goals of the Guideline**

  • Standardize the evaluation process across transplant centers to ensure consistency.
  • Optimize patient outcomes by identifying the most appropriate candidates.
  • Reduce disparities in access to liver transplantation.
  • Support informed decision-making for both patients and healthcare providers.

### Summary

The AASLD–AST guideline serves as a practical and ethical framework for evaluating adult liver transplant candidates. It stresses the importance of timely referral, comprehensive multidisciplinary evaluation, and addressing modifiable risk factors. By prioritizing equity and patient benefit, the guideline aims to improve outcomes and ensure fair access to this life-saving therapy.

Related Q&A

Synbiotics After Liver Transplant Show No Clinical Benefit: Liver Transplant | July 2026

Introduction: Bacterial infections remain a major cause of morbidity after liver transplantation despite advances in perioperative care. Synbiotics, combining probiotics and prebiotics, have been proposed to reduce postoperative infections by restoring gut microbiota and strengthening...

Tranexamic Acid in Liver Transplantation: Liver Transplant | June 2026

Introduction: Perioperative bleeding remains a major challenge during orthotopic liver transplantation (OLT), largely due to hyperfibrinolysis and coagulation abnormalities. Although tranexamic acid (TXA) effectively reduces bleeding in several surgical settings, its routine prophylactic use during...

Whole-Organ Donor Liver Assessment Using PS-OCT: Science Translational Medicine | July 2026

Introduction: Liver transplantation is limited by a shortage of suitable donor organs. Current viability assessment relies on needle biopsy, which samples only a small portion of the liver and may miss important regional pathology. This...

Personalizing Antifibrinolytic Use in Liver Transplantation : Liver Transpl | Jul 2026

Introduction: Bleeding remains a major challenge during liver transplantation despite advances in surgical techniques, anesthesia, and perioperative care. Antifibrinolytic agents have long been used to reduce intraoperative blood loss and transfusion requirements. However, evolving transplant...

Integrating LDLT into Modern Liver Transplant Programs: Liver Transplantation | June 2026

Introduction: The demand for liver transplantation continues to exceed the availability of deceased donor organs, resulting in prolonged waiting times and preventable waitlist mortality. This perspective discusses how living donor liver transplantation (LDLT) can complement...

Post-Transplant Management in Pediatric LT: Liver Transplantation | June 2026

Introduction: Pediatric liver transplantation has achieved excellent survival rates, shifting the focus from graft survival alone to optimising long-term health, growth, neurodevelopment, and quality of life. This updated guideline provides evidence-based recommendations for comprehensive care...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer